- Home
- TDUP vs DSGN Comparison
TDUP vs DSGN Comparison
Compare TDUP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | DSGN |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.9M | 853.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TDUP | DSGN |
|---|---|---|
| Price | $3.21 | $13.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $8.17 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 2.3M | 490.1K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $310,813,000.00 | N/A |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $10.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.53 | N/A |
| 52 Week Low | $3.04 | $4.23 |
| 52 Week High | $12.28 | $17.25 |
Technical Indicators
Market Signals| Indicator | TDUP | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 20.71 | 59.73 |
| Support Level | $3.08 | $9.78 |
| Resistance Level | $5.13 | $17.10 |
| Average True Range (ATR) | 0.35 | 0.73 |
| MACD | -0.22 | 0.15 |
| Stochastic Oscillator | 1.62 | 86.70 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.